General Information of Drug (ID: DM03LWZ)

Drug Name
CVX-060 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM03LWZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Angiopoietin-2 (ANGPT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Faricimab DM83SEB Diabetic macular edema 9B71.02 Approved [2]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [3]
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [4]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [5]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [6]
LY3127804 DMAC457 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [7]
REGN910-3 DMTBRPO Neovascular age-related macular degeneration 9B78.3Z Phase 2 [8]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [9]
CVX-241 DMV74JC Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
REGN-910 DMHR7D4 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of CovX (2011).
2 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
5 Company report (Roche pipeline: July 27, 2017)
6 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
9 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
10 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
11 Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.